André Zimerman
1.2K posts
@AndreZimerman
Head of Clinical Trials, @hospitalmoinhos 🇧🇷 | Professor, PG Cardiology, @ufrgsnoticias 🇧🇷 | Fellowship, @TIMIStudyGroup 🇺🇸 | Lipids, Trials, Cardiology
When TG reach ≥10 mmol/L, the question is no longer only lipid lowering. It is #pancreatitis prevention. At #EASCongress2026, @AndreZimerman presents CORE TIMI 72a and CORE2 TIMI 72b data on #olezarsen in patients with TG ≥10 mmol/L and acute pancreatitis risk @TIMIStudyGroup
#Research letter: Earlier initiation of the PCSK9 inhibitor Evolocumab reduced the risk of arterial aneurysm events compared with delayed initiation in an analysis of the FOURIER trial ahajrnls.org/3PCdvbV
Buddy of mine said he was thinking about trying ozempic but he realized that if ozempic works by suppressing your hunger signals, then you could achieve the same thing just by ignoring them. He lost something like 50 pounds in the next few months after this enlightenment.
The PhysioSync-HF trial investigates conduction system pacing as a potentially more effective & affordable alternative to traditional cardiac resynchronization therapy. Tune into #ACCEL Lite episode for more insights ➡️ bit.ly/4qxh6pp @DrJMarine @AndreZimerman #CardioX
@AndreZimerman A comprehensive presentation of your work. Thank you. Conduction system pacing for resynchronization is not deep septal pacing so one fifth of patients were ineligible to be included for the analysis to lead to the conclusion. Plus with less costly procedure you can walk farther.
Did the PhysioSync-HF trial dampen enthusiasm for CSP?
